Semanteon Capital Management LP Acquires Shares of 43,016 AxoGen, Inc. (NASDAQ:AXGN)

Semanteon Capital Management LP bought a new position in AxoGen, Inc. (NASDAQ:AXGN) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 43,016 shares of the medical equipment provider’s stock, valued at approximately $603,000. Semanteon Capital Management LP owned 0.10% of AxoGen at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the stock. nVerses Capital LLC purchased a new stake in AxoGen during the 3rd quarter worth $56,000. Koss Olinger Consulting LLC purchased a new position in AxoGen in the second quarter valued at about $75,000. Lazard Asset Management LLC grew its stake in AxoGen by 30.1% during the 1st quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after purchasing an additional 2,671 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of AxoGen in the 2nd quarter valued at approximately $125,000. Finally, BNP Paribas Financial Markets boosted its stake in shares of AxoGen by 8.6% during the 1st quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock valued at $168,000 after buying an additional 1,651 shares during the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on AXGN. StockNews.com raised shares of AxoGen from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. JMP Securities lifted their target price on AxoGen from $17.00 to $20.00 and gave the stock a “market outperform” rating in a research report on Friday, August 9th. Finally, Raymond James assumed coverage on shares of AxoGen in a research report on Monday, July 1st. They set an “outperform” rating and a $13.00 price objective for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, AxoGen has a consensus rating of “Buy” and an average target price of $15.00.

AxoGen Stock Up 4.7 %

AXGN stock opened at $13.94 on Tuesday. The company has a quick ratio of 2.32, a current ratio of 3.51 and a debt-to-equity ratio of 0.70. The firm’s 50-day simple moving average is $13.55 and its 200 day simple moving average is $9.70. The stock has a market cap of $609.25 million, a PE ratio of -27.88 and a beta of 1.13. AxoGen, Inc. has a fifty-two week low of $3.45 and a fifty-two week high of $15.23.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10. The business had revenue of $47.91 million during the quarter, compared to the consensus estimate of $43.27 million. AxoGen had a negative return on equity of 17.30% and a negative net margin of 9.53%. As a group, sell-side analysts predict that AxoGen, Inc. will post -0.33 EPS for the current year.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.